Your browser is no longer supported. Please, upgrade your browser.
ANAB AnaptysBio, Inc. daily Stock Chart
AnaptysBio, Inc.
Index- P/E- EPS (ttm)-1.29 Insider Own1.30% Shs Outstand23.56M Perf Week-3.70%
Market Cap2.65B Forward P/E- EPS next Y-2.94 Insider Trans0.00% Shs Float23.08M Perf Month-9.80%
Income-22.50M PEG- EPS next Q-0.46 Inst Own- Short Float5.40% Perf Quarter27.86%
Sales10.00M P/S265.14 EPS this Y-438.10% Inst Trans31.91% Short Ratio4.27 Perf Half Y257.84%
Book/sh13.30 P/B8.46 EPS next Y-26.70% ROA-16.90% Target Price145.71 Perf Year324.20%
Cash/sh10.54 P/C10.67 EPS next 5Y- ROE-19.10% 52W Range18.15 - 134.00 Perf YTD11.74%
Dividend- P/FCF- EPS past 5Y- ROI-6.60% 52W High-16.01% Beta-
Dividend %- Quick Ratio17.90 Sales past 5Y- Gross Margin- 52W Low520.05% ATR7.70
Employees60 Current Ratio17.90 Sales Q/Q7.10% Oper. Margin- RSI (14)44.53 Volatility5.15% 6.29%
OptionableYes Debt/Eq0.05 EPS Q/Q117.30% Profit Margin- Rel Volume2.06 Prev Close112.06
ShortableYes LT Debt/Eq0.02 EarningsMar 13 BMO Payout- Avg Volume291.69K Price112.54
Recom1.50 SMA20-6.52% SMA50-0.76% SMA20077.90% Volume600,461 Change0.43%
Mar-06-18Reiterated Stifel Buy $130 → $139
Feb-15-18Reiterated SunTrust Buy $115 → $162
Jan-23-18Reiterated Credit Suisse Outperform $85 → $135
Nov-15-17Initiated SunTrust Buy $115
Nov-09-17Initiated Jefferies Buy $101
Oct-11-17Reiterated RBC Capital Mkts Outperform $40 → $79
Sep-15-17Initiated RBC Capital Mkts Outperform $40
Jul-11-17Initiated Robert W. Baird Outperform $36
Feb-21-17Initiated Wedbush Outperform $28
Feb-21-17Initiated Stifel Buy $30
Feb-21-17Initiated JMP Securities Mkt Outperform $45
Feb-21-17Initiated Credit Suisse Outperform $34
Mar-15-18 07:31AM  Better Know Biotech: 3 Highfliers That Ought to Be on Your Radar Motley Fool
Mar-06-18 02:02PM  AnaptysBio Gears Up For an Eventful Year Motley Fool
Mar-05-18 04:15PM  AnaptysBio Announces Fourth Quarter and Full Year 2017 Financial Results and 2018 Pipeline Milestones GlobeNewswire -7.45%
Feb-26-18 09:25AM  George Soros Just Bought These 2 Biotech Stocks. Should You? Motley Fool
Feb-17-18 05:00PM  AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting GlobeNewswire
Feb-07-18 04:44PM  Here's Why AnaptysBio, Inc. Stock Surged on Wednesday Motley Fool +9.36%
06:30AM  AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting GlobeNewswire
Jan-18-18 07:40AM  Investor Expectations to Drive Momentum within Martin Marietta Materials, AnaptysBio, Hope, Agilysys, Albany International, and Goldman Sachs BDC Discovering Underlying Factors of Influence GlobeNewswire
Jan-02-18 08:00AM  The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt Zacks
06:30AM  AnaptysBio Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference GlobeNewswire
Dec-29-17 02:40PM  5 Best Performing IPOs of 2017 Zacks
Dec-28-17 08:23AM  The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical Zacks
Nov-07-17 06:00AM  AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates GlobeNewswire
Nov-06-17 04:15PM  AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results GlobeNewswire
Oct-31-17 06:30AM  AnaptysBio to Participate in Upcoming Investor Conferences GlobeNewswire
Oct-12-17 06:45PM  AnaptysBio Announces Pricing of Public Offering GlobeNewswire
07:30AM  Featured Company News - AnaptysBio Announces Positive Interim Data from Phase-2a Clinical Trial of ANB020 for Treating Atopic Dermatitis ACCESSWIRE
Oct-11-17 09:46AM  Company News For Oct 11, 2017 Zacks
Oct-10-17 04:57PM  This Biotech Hit Record High; Could Undercut Regeneron In Eczema Investor's Business Daily +101.17%
04:20PM  AnaptysBio Files Registration Statement for Proposed Public Offering GlobeNewswire
11:38AM  Here's Why AnaptysBio Inc. Is Rocketing Higher Today Motley Fool
06:30AM  AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis GlobeNewswire
Oct-02-17 10:40AM  ETFs with exposure to AnaptysBio, Inc. : October 2, 2017 Capital Cube
Sep-22-17 10:15AM  ETFs with exposure to AnaptysBio, Inc. : September 22, 2017 Capital Cube
Sep-18-17 02:16PM  RBC Capital's Marc Harris breaks down his best biotech pi... CNBC Videos +11.63%
Sep-11-17 08:24PM  ETFs with exposure to AnaptysBio, Inc. : September 12, 2017 Capital Cube
Sep-08-17 03:51PM  AnaptysBio, Inc. :ANAB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017 Capital Cube
Sep-01-17 10:35PM  AnaptysBio, Inc. Value Analysis (NASDAQ:ANAB) : September 2, 2017 Capital Cube +5.76%
Aug-29-17 08:36AM  AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : August 29, 2017 Capital Cube
Aug-24-17 08:00AM  AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors GlobeNewswire +5.44%
Aug-10-17 04:30PM  AnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates GlobeNewswire
Aug-09-17 08:57AM  Should You Buy AnaptysBio (ANAB) Ahead of Earnings? Zacks
Aug-08-17 06:30AM  AnaptysBio to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire -5.49%
Jul-31-17 09:58AM  AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : July 31, 2017 Capital Cube
Jul-24-17 01:59PM  ETFs with exposure to AnaptysBio, Inc. : July 24, 2017 Capital Cube +12.07%
Jul-14-17 12:47PM  ETFs with exposure to AnaptysBio, Inc. : July 14, 2017 Capital Cube
Jul-13-17 08:53AM  AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : July 13, 2017 Capital Cube
Jun-28-17 03:18PM  AnaptysBio, Inc. Value Analysis (NASDAQ:ANAB) : June 28, 2017 Capital Cube
Jun-27-17 08:23AM  AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : June 27, 2017 Capital Cube
Jun-09-17 08:50AM  Why AnaptysBio (ANAB) Could Be Positioned for a Slump Zacks
Jun-01-17 06:30AM  AnaptysBio to Participate in Upcoming Investor Conferences GlobeNewswire
May-29-17 08:21AM  AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 29, 2017 Capital Cube
May-11-17 04:30PM  AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update GlobeNewswire
08:57AM  AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 11, 2017 Capital Cube
Apr-20-17 02:47PM  AnaptysBio, Inc. Value Analysis (NASDAQ:ANAB) : April 20, 2017 Capital Cube
Apr-19-17 08:29AM  AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017 Capital Cube
Apr-06-17 08:00AM  AnaptysBio Announces First-In-Human Dosing of ANB019 GlobeNewswire
Apr-05-17 04:17PM  ETFs with exposure to AnaptysBio, Inc. : April 5, 2017 Capital Cube
Mar-30-17 04:34PM  Will Snap, MuleSoft IPOs Kick Up A Stampede Of Tech Unicorns? Investor's Business Daily
12:35PM  Q1 IPOs Raised $10 Billion
Mar-20-17 11:29AM  AnaptysBio, Inc. :ANAB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
Mar-16-17 10:18AM  AnaptysBio, Inc. :ANAB-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Capital Cube
Mar-14-17 01:04PM  ANAPTYSBIO INC Financials
Mar-08-17 04:33PM  ANAPTYSBIO INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:30PM  AnaptysBio Announces 2016 Operating Results and Pipeline Progress GlobeNewswire
Mar-04-17 03:00PM  AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting GlobeNewswire
Mar-02-17 06:11AM  ANAPTYSBIO INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-21-17 06:37AM  Coverage initiated on AnaptysBio by Credit Suisse, Wedbush, Stifel and JMP Securities
Feb-14-17 09:20AM  Biotech IPOs Slow As Trump-Sown Uncertainty Rattles Nerves On Wall Street Forbes
Feb-13-17 08:00AM  AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings GlobeNewswire
Feb-06-17 12:31PM  Robust Start for Pharmaceutical IPOs In 2017 Investopedia +7.47%
Feb-02-17 05:16PM  [$$] Braeburn Pharmaceuticals Puts IPO Plans On Hold The Wall Street Journal
Jan-31-17 05:00PM  AnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-29-17 11:39PM  [$$] Shares in Two Biotechs Rise Post-IPO at The Wall Street Journal
09:38AM  IPO Market Looking for 7 Offerings This Week
Jan-27-17 02:05PM  After $97M IPO, Swiss biotech to open U.S. headquarters in Boston at
06:15AM  Cambridges Jounce raises hopes as first Mass. biotech of 2017 to go public at
Jan-25-17 07:00PM  AnaptysBio Announces Pricing of Initial Public Offering GlobeNewswire
AnaptysBio, Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. It is developing ANB020, a pro-inflammatory cytokine antibody that inhibits the activity of interleukin-33; and ANB019, an antibody that inhibits the function of the interleukin-36-receptor. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lydon NicholasDirectorFeb 15Option Exercise4.5516,48374,998304,106Feb 20 04:08 PM